Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          

SB05

SB05

SB05 is a positively charged liposome embedded with paclitaxel which against pancreatic cancer and triple negative breast cancer.

Request for Collaboration
Overview
SB05 is an innovative composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Due to the positively charged lipids, SB05 interacts with newly developing, negatively charged endothelial cells, which are especially required for the growth of tumor blood vessels. The SB05 paclitaxel component attacks the activated endothelial cells as they divide, thus targeting the blood supply to tumors without affecting the supply to not activated endothelial cells of healthy tissue. By doing this, SB05 is expected to prevent the formation of new tumor blood vessels and to inhibit tumor growth.
 
  • Promising phase II results agaist pancreatic cancer and TNBC with favorable safety profile
  • Pancreatic cancer orphan drug designation has granted by US FDA and EMA
  • Ready for global phase III
Application
Potential indications:
 
  • Pancreatic cancer
  • Triple negative breast cancer
Collaboration Options
  • Co-develop
  • Tech-transfer
  • Commercialize
  • Licensing
People who like this also like
  • FB825FB825
  • TLC599TLC599
  • EG12014 Trastuzumab BiosimilarEG12014 Trastuzumab Biosimilar
  • PixoTest technologyPixoTest technology
  • TRIA11TRIA11
  • FuraprevirFuraprevir
  • Medical Image Playing System and MethodMedical Image Playing System and Method
  • PHN014 (Acute ischemia stroke)PHN014 (Acute ischemia stroke)
  • Isoniazid without liver toxicityIsoniazid without liver toxicity
  • TAH9922 ADHD Oral SolutionTAH9922 ADHD Oral Solution